A study lead by researchers at the Institute of HIV Research, Medical Faculty of UDE and University Hospital Essen reports a potential toxicity of integrase inhibitors. Integrase inhibitors (INSTI) are a preferred drug for inclusion in anti-retroviral therapy regimens given its tolerability, efficacy and high resistance barrier. INSTI have been found to improve and prolong lives of millions of people living with HIV who suffer side-effects and resistance to treatment. However, recent laboratory data suggest that INSTI may not be as safe as suggested.
* This article was originally published here
